Since its inception in 2000, metronomic chemotherapy has undergone major advances as
an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy …

Children and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous
population with variable overall survival rates ranging between approximately 6% and 100 …

Background For more than three decades, standard treatment for rhabdomyosarcoma in
Europe has included 6 months of chemotherapy. The European paediatric Soft tissue …

Background Rhabdomyosarcoma is an aggressive tumour that can develop in almost any
part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in …

Purpose The overall survival (OS) of patients with relapsed Ewing's sarcoma family of
tumors (ESFT) is poor, and the relative benefit of high-dose therapy (HDT) is controversial …

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With
Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s …

Radiotherapy is the only treatment definitely indicated for diffuse pontine gliomas (DIPG).
Findings on the role of EGFR signaling in the onset of childhood DIPG prompted the use of …

Triggered drug delivery strategies have been shown to enhance drug accumulation at target
diseased sites in comparison to administration of free drug. In particular, many studies have …

Relapsed rhabdomyosarcoma (RMS) represents a significant therapeutic challenge. Nearly
one-third of patients diagnosed with localized RMS and over two-thirds of patients with …

Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach,
incorporating chemotherapy with local control. Although current therapies are built on …